View Older Stories View More Recent Stories
-
ESSA Pharma Inc. reports financial results for the first quarter ended December 31, 2015
-
Form 4 ZAFGEN, INC. For: Feb 09 Filed by: DEERFIELD MANAGEMENT CO
-
KemPharm Announces Closing of $86.25 Million 5.50% Senior Convertible Notes Due 2021
-
Flamel Technologies Acquires FSC Pediatrics
-
Form 4 Editas Medicine, Inc. For: Feb 08 Filed by: DEERFIELD MANAGEMENT CO
-
KemPharm Announces Pricing of $75.0 Million 5.50% Senior Convertible Notes Due 2021
-
Deerfield Management and Oxeon Unlock the Power of Women in the Boardroom
-
Deerfield Finances Pioneer in 3D Printing for Pharmaceuticals
-
Aprecia Pharmaceuticals Set to Advance 3D Printed Drug Pipeline with Completion of $35 Million Financing Led by Deerfield Management
-
Nuo Therapeutics Inc. Commences Voluntary Chapter 11 Business Reorganization
-
ESSA Pharma Announces Closing of US$15 Million Private Placement
-
Syros Pharmaceuticals Closes $40 Million Preferred Stock Financing
-
Nuo Therapeutics Announces Senior Management Change and Provides Limited Corporate Update
-
Deerfield Advances Healthcare Through the Publication of Novel Findings
-
Xeris Pharmaceuticals Announces $41 Million Series C Financing
-
ESSA Pharma (EPIX) Plans $15M Units Private Placement
-
ESSA Pharma announces proposed US$15 million private placement
-
Nuo Therapeutics Announces Execution of Third Limited Consent With Deerfield Management Through January 7, 2016
-
Deerfield Announces Partnership with Recovery Centers of America
-
Deerfield Leads Series A in Hallux, Inc.
-
Recovery Centers of America Raises $231.5 Million to Revolutionize Addiction Treatment and Behavioral Healthcare and Become One of the World’s Largest Providers by Bringing Comprehensive Centers for
-
Hallux Announces Closing of $7.1 Million Series A Financing
-
Nuo Therapeutics Announces Appointment of Chief Restructuring Officer
-
Form 4 DEERFIELD MANAGEMENT CO For: Dec 04 Filed by: ALIMERA SCIENCES INC
-
Nuo Therapeutics Announces Execution of Second Limited Consent With Deerfield Management Through December 17, 2015
-
Nuo Therapeutics Announces Execution of Second Limited Consent With Deerfield Management Through December 17, 2015
-
Fractyl Announces Completion of $57 Million Series C Investment
-
Form 13F-HR DEERFIELD MANAGEMENT CO For: Sep 30
-
Nuo Therapeutics Announces Execution of Limited Consent With Deerfield Management Through December 4, 2015
-
Nuo Therapeutics Announces 3rd Quarter 2015 Financial Results
-
Nuo Therapeutics Announces Execution of Limited Consent With Deerfield Management Through December 4, 2015
-
Nuo Therapeutics Announces 3rd Quarter 2015 Financial Results
-
Discovery Labs Provides Business Update and Reports Third Quarter 2015 Financial Results
-
Nuo Therapeutics to Hold Third Quarter 2015 Conference Call on Friday, November 13 at 8:00 a.m. Eastern Time
-
Conventus Orthopaedics Raises $23.5 Million to Fuel Conventus Cage Commercialization and Technology Development
-
Nuo Therapeutics Responds to Favorable CMS Hospital Outpatient Payment Final Ruling for Aurix System
-
Nuo Therapeutics Responds to Favorable CMS Hospital Outpatient Payment Final Ruling for Aurix System
-
Deerfield Management Announces Partnership with Gregory Sorensen and Deerfield Imaging
-
AAC Holdings, Inc. Reports Third Quarter 2015 Results
-
Nuo Therapeutics Executes Amended Licensing Agreement With Arthrex
-
Audentes Therapeutics Raises $65 Million in Series C Financing
-
Unusual 11 Mid-Day Movers 10/12: (MBLX) (ALIM) (NVCR) Higher; (MHR) (SXC) (BCEI) Lower
-
Janet S. Vergis Appointed to Impax Laboratories Board of Directors
-
PlacementTracker Publishes Third Quarter 2015 PIPE Market League Tables
-
Breathe Technologies, Inc. Will Present And Exhibit At Upcoming Medical Technology Conferences
-
Deerfield Makes $50 Million Commitment to AAC Holdings to Expand Clinical Care and Treatment with Additional $50 Million Incremental Facility
-
AAC Holdings Enters into $50 Million Capital Commitment with Deerfield Management and an Additional $50 Million Incremental Facility
-
U.S. biotech bloodbath hits hedge funds but some bargains emerge
-
Form 4 REGENXBIO Inc. For: Sep 22 Filed by: DEERFIELD MANAGEMENT CO
-
Deerfield Leads Funding in Creation of Akari Therapeutics

